Transcatheter aortic valve replacement (TAVR) has revolutionized the management of severe aortic stenosis (AS) in patients who are at high risk or ineligible for surgical aortic valve replacement (SAVR). The Edwards SAPIEN (Edwards Lifesciences, Irvine, California) transcatheter heart valve (THV) with its RetroFlex 3 delivery system, the first clinically available TAVR device in the United States, was approved by the US Food and Drug Administration for transfemoral (TF) TAVR in patients with inoperable, severe AS. However, a significant proportion of patients who would otherwise qualify for TAVR (up to 30% in the PARTNER [Placement of Aortic Transcatheter Valves] trial [1] ) are excluded because of inadequate iliofemoral vascular access. In these patients, the transapical (TAP) route was the alternative method of device delivery. Unfortunately, early experience with TAP TAVR suggests a trend toward less favorable periprocedural outcomes (2) and a steep learning curve (3) . Thus, other access strategies need to be explored. We describe our initial experience with the transaortic (TAO) TAVR approach for the treatment of these patients.
Methods
Forty-four consecutive patients underwent TAO TAVR between January 2012 and June 2012 at our site and were enrolled in a prospective database. All patients had symptomatic (New York Heart Association class II to IV), inoperable, severe AS and inadequate TF vascular access. Severe AS was defined according to PARTNER trial criteria (4), as was inoperability that was formally determined by at least 2 cardiothoracic surgeons. Iliofemoral access was deemed inadequate if the minimum vessel diameter was <7 mm for a 23-mm valve (<8 mm for a 26-mm valve) or if there were vascular anatomic abnormalities that precluded TF device delivery. The TAO TAVR procedure was performed in a hybrid cardiac catheterization laboratory under general anesthesia (Fig. 1) . The operative steps are listed in Table 1 . Study outcomes. The main study outcomes were Valve Academic Research Consortium-defined acute technical device success and 30-day combined safety endpoint. Acute technical device success was defined as successful vascular access, successful delivery and deployment of a single valve at the correct anatomic position, and appropriate prosthetic valve function without significant (moderate or severe) perivalvular regurgitation or stenosis; these assessments were made by using echocardiography immediately after valve deployment and before hospital discharge. The combined safety outcome is a hierarchical composite of all-cause mortality, major stroke, disabling bleeding, severe (stage 3) acute kidney injury, postprocedure myocardial infarction, major vascular complication, and repeat procedure for valverelated dysfunction.
To evaluate the technical learning curve, the hierarchical composite of intraprocedural adverse events (procedural death, rescue cardiac surgery, valve reintervention, lifethreatening hemorrhage, major vascular complications, myocardial infarction, and major stroke) was used to compare the first 20 cases with the subsequent patients who underwent the operation. Length of stay (LOS) at the intensive care unit (ICU) and total hospital LOS were also recorded. All events were adjudicated by using the Valve Academic Research Consortium criteria (5) . Comparator cohort. To evaluate the effect of the technical learning curve and clinical safety of the TAO TAVR approach, outcomes data were compared with data from 76 consecutive patients who underwent TAP TAVR at our site from May 2009 to June 2012. TAP TAVR was performed by using the SAPIEN THV and its dedicated Ascendra delivery system, as described elsewhere (1) . Statistical analysis. Absolute numbers, percentages, and medians were calculated to describe the population. For comparisons between groups, the Mann-Whitney U test for continuous variables and the chi-square test or Fisher exact test for categorical variables were used. A 2-tailed p value of 0.05 was considered to indicate statistical significance.
Results
The baseline demographic and clinical profiles of patients in both groups were generally similar ( Table 2 ). The TAP group had a higher median Society of Thoracic Surgeons (STS) score, driven by a higher proportion of patients who had previous coronary artery bypass graft and stroke. All patients in the TAO group were deemed inoperable, whereas most patients in the TAP group were eligible for SAVR.
THV implantation was successful in all patients in the TAO and TAP groups. Thirty-nine patients (89%) in the TAO group met the Valve Academic Research Consortiumdefined criteria for acute technical device success, compared with 64 (84%) in the TAP group (p ¼ 0.59). The proportion of patients with significant residual perivalvular regurgitation was also similar between groups (Table 3 ). In the TAP group, 3 cases (4%) of valve malposition/embolization occurred, and 5 patients (7%) required rescue valve-in-valve TAVR. No such device-related complications were reported in the TAO group.
One patient in the TAO group and 2 patients in the TAP group died during the procedure. Two of these deaths (1 in each group) resulted from aortic root perforation during valve deployment. The other intraoperative mortality in the TAP group was due to myocardial infarction resulting from obstruction of the left coronary ostium by the implanted prosthesis.
At 30 days, the combined safety endpoint was similar between the TAO and TAP groups (20% vs. 33%, respectively; p ¼ 0.21). Rates of all-cause death were identical between Table 1 Step-by-Step Description of the TAO TAVR Procedure A 2-inch midline skin incision was made on the chest just below the sternal notch.
A limited, upper "mini-J" sternotomy was performed at the second intercostal space.
The innominate vein was identified and mobilized to expose the ascending aorta below.
A suitable, noncalcified area for aortotomy was identified.
A double purse-string suture of 4-0 Prolene was placed over the aortotomy site.
Intravenous heparin was administered for anticoagulation.
An 18-gauge needle was used to puncture the ascending aorta at the aortotomy site.
A short 7-F sheath was inserted through the aortotomy over a guidewire.
The aortic valve was crossed with a 6-F pigtail catheter.
The catheter was exchanged with a 0.035-inch Amplatz Extra-Stiff guidewire*.
The 7-F sheath was exchanged with the RetroFlex 3 introducer sheath.
The introducer tip was advanced about 1 cm into the ascending aorta.
Balloon aortic valvuloplasty was performed by using an Edwards 23 Â 30 mm balloon catheter.
The transcatheter aortic valve prosthesis was deployed by using the RetroFlex 3 delivery catheter.
The introducer sheath was removed, and the purse-string sutures were tied to seal the aortotomy.
A chest tube was inserted in the pericardium left of the aorta, exiting through the right chest.
*Before insertion, the distal end of the stiff guidewire was bent into a large semicircular shape to reduce risk of ventricle perforation. TAO ¼ transaortic; TAVR ¼ transcatheter aortic valve replacement. Lardizabal et al. June 11, 2013 June 11, :2341 Transaortic TAVR: Initial U.S. Clinical Experience groups. Only 1 (17%) of the 6 deaths in the TAO group was cardiovascular (CV)-related (intraprocedural mortality), whereas 9 (82%) of the 11 deaths in the TAP group were adjudicated as CV mortality (p ¼ 0.02). Causes of non-CV deaths in the TAO group were pneumonia-related respiratory failure (4 cases) and Clostridium difficile sepsis (1 case).
The incidence of life-threatening/disabling bleeding did not differ between groups. However, the rate of major bleeding was higher in the TAP group compared with the TAO group (28% vs. 11%, respectively; p ¼ 0.04), as was the incidence of total bleeding and vascular complications (46% vs. 27%, respectively; p ¼ 0.05). On average, patients in the TAP group stayed twice as long in the ICU as the TAO group (6 vs. 3 days; p ¼ 0.01). Median hospital LOS was also lower in the TAO group, but this finding was not statistically significant (Fig. 2) .
The rates of composite intraprocedural adverse events did not differ between the first 20 cases and the subsequent 56 patients who underwent TAP TAVR (15% vs. 14%, respectively; p ¼ 0.99). However, procedural adverse events occurred exclusively in the first 20 patients who underwent TAO TAVR (20% vs. 0%; p ¼ 0.04), suggesting a more favorable technical learning curve (Fig. 3) .
Discussion
Although the TAP approach is an effective option for TAVR (6), the need for alternative access strategies remains. In the FRANCE 2 (French Aortic National CoreValve and Edwards) Registry (7) of nearly 3,200 TAVR patients, TAP access was an independent predictor of decreased survival. Also, a trial that sought to compare TAP TAVR with conventional SAVR was prematurely terminated due to excess adverse events with the TAP approach (2).
Our findings demonstrate that the TAO approach is technically feasible in patients with inoperable, severe AS who are ineligible for TF TAVR. In our cohort, TAO TAVR was associated with lower bleeding rates, shorter ICU stay, and more favorable learning curve compared with the TAP approach.
Multiple transfusions during cardiac surgery are associated with increased mortality and morbidity (8) . Efforts to reduce operative blood loss are likely as important in TAVR. In 28% of TAP patients in our series, significant blood loss occurred during access site closure. In the TAP approach, hemostasis at the left ventricular apex was sometimes difficult to attain by using purse-string sutures. This does not seem to be an issue with the TAO approach, as the double purse-string sutures provided excellent seal of the aortotomy (a routine maneuver for cardiothoracic surgeons who are experienced with cannulating the aorta). This success contributed to a significant 61% relative reduction in perioperative blood transfusions in TAO TAVR compared with TAP TAVR.
A cost-effectiveness analysis of the PARTNER trial found that TAP TAVR was associated with substantially The intensive care unit (ICU) and hospital lengths of stay (LOS) using the transcatheter aortic valve replacement (TAVR) approach are displayed. ICU LOS was significantly lower in the transaortic (TAO) group than in the transapical route (TAP) group. There was also a nonsignificant trend toward lower total hospital LOS with TAO TAVR.
Figure 3 Learning Curve
The procedural learning curve outcomes according to the TAVR approach are presented. In the TAO group (top), procedural adverse events were significantly reduced after the first 20 cases. This observation was not seen in the TAP group (bottom). Abbreviations as in Figures 1 and 2 .
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Transaortic TAVR: Initial U.S. Clinical Experience June 11, 2013 June 11, :2341 higher overall costs compared with SAVR because of minimal reduction in ICU and hospital LOS (9) . This information is vital for any institution starting a TAVR program. In our series, ICU LOS was significantly longer in TAP TAVR patients, owing to a longer duration of severe surgical site pain and higher incidence of significant postthoracotomy pleural effusion that complicated postoperative pulmonary function.
As with other new devices and modalities, TAVR requires a certain period for operator training and familiarization. In our study, the technical learning curve for TAO TAVR seemed favorable, as major intraprocedural adverse events were effectively averted after the first 20 cases. There was also a trend toward a reduction in clinical events and mortality in the TAO group with increasing operator experience. This pattern was not observed with TAP TAVR, implying a steeper learning curve and a larger number of procedures required for proficiency. A significant learning effect was previously demonstrated in a cohort of approximately 300 TAP TAVR patients, in whom a sharp decline in morbidity and mortality was noted after the first 150 cases (3).
Device malposition was reported in 3 patients and need for second THV implantation was required in 5 patients, all in the TAP group. Left ventricular contractions induced significant movement of the introducer sheath in the TAP route, which made manipulation and positioning of the THV across the native valve difficult. Conversely, we observed very little movement of the introducer sheath with TAO access, resulting in more stable and controlled positioning and deployment of the THV.
To the best of our knowledge, our series is the largest cohort of patients who underwent TAO TAVR in the United States to date. A similar preliminary experience was reported in Europe with comparable clinical outcomes (10) . However, the European study used a newer-generation THV (SAPIEN XT) and delivery system (Ascendra2), which were not available in the United States at the time of the study. Our TAO TAVR program was discontinued with implementation of the 2012 Medicare national coverage determinations for TAVR (11) . Our study was completed before the Ascendra delivery system (the original TAP platform) was approved by the U.S. Food and Drug Administration for clinical use in the United States, and therefore comparative data between the use of TF and TAP delivery devices in TAO TAVR are lacking. Finally, the use of delivery systems not specifically designed for TAO TAVR can lead to technical issues during device delivery (12) . Therefore, development of a dedicated delivery system for TAO TAVR is recommended to improve the safety and efficacy of this procedure. Study limitations. This was a nonrandomized, single-center registry study that is subject to unmeasurable confounders. The comparison of patients was taken from 2 different time periods, which may have influenced the learning curve for the TAO procedure. The TAP group also had a higher median STS score compared with the TAO group, and this finding could also have potentially influenced the outcomes. Larger randomized clinical trials are necessary to confirm our results.
Conclusions
TAVR via the TAO approach, using the device commercially available in the United States, is technically feasible and seems to be associated with favorable outcomes in patients with inoperable, severe AS who are not candidates for TF access. The TAO approach expands the current alternative options for TAVR access sites, and development of a dedicated delivery platform is recommended to further improve its efficacy and safety.
